Amy Moore, Director of Patient Engagement and Advocacy at Summit Therapeutics, shared a post by Oncogene Cancer Research on LinkedIn, adding:
“When I think about what the future of lung cancer looks like, I have great hope because of the work of people like Professor Charles Swanton. I first came to know him through Cancer Grand Challenges and his work on the role of air pollution and PM2.5 particles in promoting lung cancer in people with existing mutations.
I am always in awe of his brilliance and learn something new every time I hear him speak or read one of his latest studies. With people like him leading the charge, we are poised to better understand the causes of lung cancer and to intercept it in its infancy, when it is most treatable, or to prevent it altogether.”
Highlighting Professor Swanton’s vision, Oncogene Cancer Research stated:
“Fewer people hearing the words ‘you have lung cancer’. Fewer families having their lives turned upside down.
That is the human hope behind Professor Charles Swanton’s vision of preventing lung cancer before it starts. At The Francis Crick Institute and University College London Hospitals NHS Foundation Trust, his research explores the earliest steps of tumour development and how understanding them could open a path to prevention.
‘We are hopeful about a future where we can prevent lung cancer before it starts by understanding the very earliest steps in tumour initiation and targeting them.’ – Professor Charles Swanton
This LCAM26, we ask the research community to keep pursuing those early questions with urgency. Behind every discovery is the possibility of sparing someone a diagnosis, treatment and the uncertainty that follows. Prevention is a future worth working towards, alongside better care for everyone living with lung cancer today.”
You can also read:
After a Decade Without a New Option, FDA Approves Amivantamab for Head and Neck Cancer
